Schrödinger is abandoning its CDC7 inhibitor after the therapy was linked to the deaths of two patients in a phase 1 leukemia ...

A patient has died from kidney injury in a trial of ’ lead antibody-drug conjugate, although the biotech has been advised to ...

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

Vedanta Biosciences’ dreams of using live bacteria to treat inflammatory bowel disease (IBD) have been dashed. | Vedanta ...

After years of being cleared on the European market, Nyxoah’s neuromodulation therapy for obstructive sleep apnea has now ...

As for recent success stories from its biotech portfolio, Hatteras namechecked Kymera Therapeutics. The VC fund contributed ...

Conformal Medical has raised $32 million to support the development of its heart implant designed to reduce the lifetime risk ...

Generation Bio is shedding 90% of its workforce after the biotech acknowledged it’s unlikely to find the cash to take its ...

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

After the Department of Health and Human Services canceled about $500 million in funding for mR | After HHS abruptly canceled ...

Clinical trial tech outfit Medidata has elevated a new strategy leader from within. | Clinical trial tech outfit Medidata has elevated a new strategy leader from within. Industry veteran Lisa ...

The director of the National Institutes of Health (NIH) has said the federal government’s discontinuation of mRNA vaccine ...